clinical trial · NCT07276425
Early and Long-Term Efficacy and Immune Changes With Dupilumab in Prurigo Nodularis
UMC Utrecht·—·recruiting·n = 40
Prurigo Nodularis (PN)Dupilumab
brief summary
With the arrival of dupilumab as the first available targeted therapy for PN, there is an unmet need for real-world data and translational research on the working mechanism of dupilumab on PN, to optimize individualized targeted treatment.
started
Jun 1, 2025
primary completion
Jun 1, 2028
completion
Jun 1, 2028
last updated
Dec 18, 2025
official title
Early and Long-term Clinical Efficacy and Local Tissue and Peripheral Immune Changes Following Dupilumab Treatment in Prurigo Nodularis Patients
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol